Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic marrow transplantation: the Seattle experience

J A Hansen1, C Anasetti, P J Martin

  • 1Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle.

Clinical Transplants
|January 1, 1993
PubMed
Summary

Allogeneic marrow transplants offer life-saving therapy but face challenges like graft-versus-host disease (GvHD) and donor matching. Improving HLA-mismatched transplants is crucial for broader patient access and successful outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.

Bone marrow transplantation·2017
Same author

Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.

Bone marrow transplantation·2016
Same author

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Bone marrow transplantation·2016
Same author

New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?

Bone marrow transplantation·2016
Same author

Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma.

Bone marrow transplantation·2015
Same author

Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience.

Bone marrow transplantation·2015

Area of Science:

  • Hematopoietic stem cell transplantation
  • Immunology
  • Transplantation medicine

Background:

  • Allogeneic marrow transplantation is a life-saving therapy for hematologic and immune diseases.
  • Graft-versus-host disease (GvHD) and opportunistic infections complicate transplants, even with HLA-identical donors.
  • Minor histocompatibility determinants and HLA mismatches increase risks of rejection and GvHD.

Purpose of the Study:

  • To review the challenges and opportunities in allogeneic marrow transplantation.
  • To highlight the critical role of HLA matching in transplant success.
  • To emphasize the need for improved strategies for HLA-mismatched transplants.

Main Methods:

  • Review of current literature on allogeneic marrow transplantation.

Related Experiment Videos

  • Analysis of the impact of HLA matching on GvHD and graft rejection.
  • Evaluation of donor registries and their limitations.

    • Main Results:

    • HLA matching is critical; increased HLA incompatibility correlates with higher GvHD incidence and severity.
    • While donor registries have improved unrelated donor matching, many patients, particularly non-White, still lack suitable matches.
    • Alternate donors (unrelated, partially matched) increase risks but offer therapeutic options.

    Conclusions:

    • Successful allogeneic transplantation requires overcoming GvHD and donor matching barriers.
    • Current donor registries are insufficient for all patient populations.
    • Advancements in managing HLA-mismatched transplants are essential for expanding access to this therapy.